FTI Consulting, Inc. announced the appointment of Michael Rachlin as a Senior Managing Director in the firm’s Valuation & Financial Advisory Services practice within the Corporate Finance & Restructuring segment. Mr. Rachlin, who will be based in New York, is an expert in life sciences, advising clients through their most critical transaction and transformation challenges. In his new role, Mr. Rachlin will lead life sciences industry efforts in the Valuation & Financial Advisory Services practice, helping clients in the biopharmaceutical, medical technology and cannabis industries evaluate transaction opportunities and larger growth-related initiatives, as well as valuation, deal modeling and strategic alternatives. Mr. Rachlin also has experience delivering customized solutions across the M&A lifecycle, including target screening, diligence, structuring, purchase accounting and post-merger integration. He designs and delivers custom solutions that address the financial needs of both large and middle-market life sciences organizations. Prior to joining FTI Consulting, Mr. Rachlin was a senior leader at Deloitte Transactions & Business Analytics, LLP, where he oversaw a range of transaction and financial advisory services for the firm’s middle-market life sciences segment, including strategy, planning, go-to-market and delivery. He is an adjunct professor at Brooklyn Law School and previously sat on the Finance Committee at BioNJ, where he focused on financial topics for pharmaceutical companies.